OvaScience (NASDAQ:OVAS) Getting Somewhat Favorable Press Coverage, Accern Reports

Media headlines about OvaScience (NASDAQ:OVAS) have been trending somewhat positive on Monday, according to Accern. The research firm scores the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. OvaScience earned a coverage optimism score of 0.16 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 45.2365636586561 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Here are some of the news articles that may have impacted Accern’s rankings:

How to Become a New Pot Stock Millionaire

Several analysts have commented on OVAS shares. Zacks Investment Research raised shares of OvaScience from a “hold” rating to a “buy” rating and set a $1.25 target price for the company in a research report on Wednesday, January 10th. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of OvaScience in a report on Friday, March 16th.

Shares of OVAS stock opened at $0.81 on Monday. OvaScience has a 52-week low of $0.79 and a 52-week high of $2.01. The firm has a market capitalization of $28.97, a PE ratio of -0.61 and a beta of 3.05.

OvaScience (NASDAQ:OVAS) last announced its quarterly earnings data on Thursday, March 15th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.07. OvaScience had a negative net margin of 17,338.78% and a negative return on equity of 60.06%. The company had revenue of $0.09 million during the quarter, compared to analysts’ expectations of $0.10 million. sell-side analysts forecast that OvaScience will post -1.21 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “OvaScience (NASDAQ:OVAS) Getting Somewhat Favorable Press Coverage, Accern Reports” was published by BBNS and is the property of of BBNS. If you are reading this news story on another publication, it was illegally copied and republished in violation of United States & international copyright law. The legal version of this news story can be viewed at https://baseballnewssource.com/2018/04/02/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-ovascience-ovas-share-price/2002749.html.

OvaScience Company Profile

OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.

Insider Buying and Selling by Quarter for OvaScience (NASDAQ:OVAS)

Receive News & Ratings for OvaScience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OvaScience and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Red Sox Tie Record for Best Start After 17 Games
Red Sox Tie Record for Best Start After 17 Games
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Rick Porcello’s Strong Start Gives Boost to Red Sox
Rick Porcello’s Strong Start Gives Boost to Red Sox
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry
Xander Bogaerts Goes on Red Sox DL
Xander Bogaerts Goes on Red Sox DL


Leave a Reply

 
© 2006-2018 BBNS.